BACKGROUND: Radiolabelled immunotherapy agents have an increasingly significant role in autologous stem cell transplantation (ASCT) by improving the tolerability and increasing the efficacy of the conditioning regimen, thereby reducing the relapse risk. We evaluated the efficacy and safety of yttrium-90-ibritumomab tiuxetan ((90)Y-ibritumomab) combined with intravenous busulfan, cyclophosphamide, and etoposide (Bu/Cy/E) followed by ASCT in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). METHODS: Each patient received a single dose of (90)Y-ibritumomab (0.4 mCi/kg on day -14) with Bu/Cy/E as a conditioning regimen. RESULTS: The patient cohort consisted of 19 individuals (ten males), of median age 51 years (range, 25-63 years). Sixteen patients had received two or more chemotherapy regimens before transplantation. Histologies were diffuse large B-cell (n = 14), follicular (n = 2), mantle cell (n = 2), and Burkitt lymphoma (n = 1). All patients engrafted. The median time to neutrophil engraftment was 10 days and time to platelet engraftment was 10 days. Nineteen patients were evaluable for response. The objective overall response rate was 84.2% (16/19): continued CR, 36.8% (7/19); induced CR, 36.8% (7/19); and PR, 10.5% (2/19). With a median follow-up of 29.4 months (13.4-36.6), the estimated 3-year overall survival and event-free survival rates were 52.6% (95% confidence interval [CI] 45.8-59.4) and 26.3% (95% CI 19.8-32.8), respectively. Adverse events were similar to those seen historically with Bu/Cy/E alone, and there were no treatment related deaths. CONCLUSION: In conclusion, (90)Y-ibritumomab with Bu/Cy/E and ASCT is feasible in patients with relapsed or refractory B-cell NHL, without increased toxicity.
BACKGROUND: Radiolabelled immunotherapy agents have an increasingly significant role in autologous stem cell transplantation (ASCT) by improving the tolerability and increasing the efficacy of the conditioning regimen, thereby reducing the relapse risk. We evaluated the efficacy and safety of yttrium-90-ibritumomab tiuxetan ((90)Y-ibritumomab) combined with intravenous busulfan, cyclophosphamide, and etoposide (Bu/Cy/E) followed by ASCT in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). METHODS: Each patient received a single dose of (90)Y-ibritumomab (0.4 mCi/kg on day -14) with Bu/Cy/E as a conditioning regimen. RESULTS: The patient cohort consisted of 19 individuals (ten males), of median age 51 years (range, 25-63 years). Sixteen patients had received two or more chemotherapy regimens before transplantation. Histologies were diffuse large B-cell (n = 14), follicular (n = 2), mantle cell (n = 2), and Burkitt lymphoma (n = 1). All patients engrafted. The median time to neutrophil engraftment was 10 days and time to platelet engraftment was 10 days. Nineteen patients were evaluable for response. The objective overall response rate was 84.2% (16/19): continued CR, 36.8% (7/19); induced CR, 36.8% (7/19); and PR, 10.5% (2/19). With a median follow-up of 29.4 months (13.4-36.6), the estimated 3-year overall survival and event-free survival rates were 52.6% (95% confidence interval [CI] 45.8-59.4) and 26.3% (95% CI 19.8-32.8), respectively. Adverse events were similar to those seen historically with Bu/Cy/E alone, and there were no treatment related deaths. CONCLUSION: In conclusion, (90)Y-ibritumomab with Bu/Cy/E and ASCT is feasible in patients with relapsed or refractory B-cell NHL, without increased toxicity.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: Ashwin Kashyap; John Wingard; Pablo Cagnoni; Jones Roy; Stephan Tarantolo; Wendy Hu; Karl Blume; Joyce Niland; Joycelynne M Palmer; William Vaughan; Hugo Fernandez; Richard Champlin; Stephen Forman; Borje S Andersson Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: O W Press; J F Eary; T Gooley; A K Gopal; S Liu; J G Rajendran; D G Maloney; S Petersdorf; S A Bush; L D Durack; P J Martin; D R Fisher; B Wood; J W Borrow; B Porter; J P Smith; D C Matthews; F R Appelbaum; I D Bernstein Journal: Blood Date: 2000-11-01 Impact factor: 22.113
Authors: Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: I W Flinn; P V O'Donnell; A Goodrich; G Vogelsang; R Abrams; S Noga; D Marcellus; M Borowitz; R Jones; R F Ambinder Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: Borje S Andersson; Ashwin Kashyap; Victor Gian; John R Wingard; Hugo Fernandez; Pablo J Cagnoni; Roy B Jones; Stefano Tarantolo; Wendy W Hu; Karl G Blume; Stephen J Forman; Richard E Champlin Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: Amrita Krishnan; Auayporn Nademanee; Henry C Fung; Andrew A Raubitschek; Arturo Molina; Dave Yamauchi; Roberto Rodriguez; Ricardo T Spielberger; Peter Falk; Joycelynne M Palmer; Stephen J Forman Journal: J Clin Oncol Date: 2007-11-19 Impact factor: 44.544
Authors: Pier F Ferrucci; Anna Vanazzi; Chiara M Grana; Marta Cremonesi; Mirco Bartolomei; Marco Chinol; Mahila Ferrari; Davide Radice; Stefano Papi; Giovanni Martinelli; Giovanni Paganelli Journal: Br J Haematol Date: 2007-11 Impact factor: 6.998
Authors: G Damaj; J Cornillon; K Bouabdallah; R Gressin; S Vigouroux; T Gastinne; F Ranchon; H Ghésquières; G Salles; I Yakoub-Agha; E Gyan Journal: Bone Marrow Transplant Date: 2017-01-23 Impact factor: 5.483